US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
IL125073A0
(en)
*
|
1996-01-08 |
1999-01-26 |
Genentech Inc |
Wsx receptor and ligands
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
US7063958B1
(en)
*
|
1996-01-16 |
2006-06-20 |
The Rockefeller University |
Nucleic acids db, the receptor for leptin
|
DK1007082T3
(en)
|
1997-01-15 |
2007-02-19 |
Phoenix Pharmacologics Inc |
Modified tumor necrosis factor
|
US6183738B1
(en)
|
1997-05-12 |
2001-02-06 |
Phoenix Pharamacologics, Inc. |
Modified arginine deiminase
|
ATE318149T1
(en)
|
1998-10-16 |
2006-03-15 |
Biogen Idec Inc |
INTERFERON-BETA-1A POLYMER CONJUGATES AND USES THEREOF
|
EA005005B1
(en)
|
1998-10-16 |
2004-10-28 |
Байоджен, Инк. |
HUMAN INTERFERON beta-1alpha HYBRID POLYPEPTIDE, MUTANTS THEREOF AND DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
EP2305314B1
(en)
|
2001-10-10 |
2015-12-23 |
ratiopharm GmbH |
Remodelling and glycoconjugation of antibodies
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
CN102180944A
(en)
*
|
2001-10-10 |
2011-09-14 |
诺和诺德公司 |
Remodeling and glycoconjugation of peptides
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
DE10209821A1
(en)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Coupling of proteins to a modified polysaccharide
|
CA2496317C
(en)
*
|
2002-09-11 |
2014-02-18 |
Fresenius Kabi Deutschland Gmbh |
Method of producing hydroxyalkyl starch derivatives
|
WO2004046309A2
(en)
|
2002-11-18 |
2004-06-03 |
Phoenix Pharmacologics, Inc. |
Methods for inhibiting viral replication in vivo
|
US7803777B2
(en)
|
2003-03-14 |
2010-09-28 |
Biogenerix Ag |
Branched water-soluble polymers and their conjugates
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US7691603B2
(en)
|
2003-04-09 |
2010-04-06 |
Novo Nordisk A/S |
Intracellular formation of peptide conjugates
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
ES2445948T3
(en)
|
2003-11-24 |
2014-03-06 |
Ratiopharm Gmbh |
Glycopegylated Erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
JP2007515410A
(en)
*
|
2003-12-03 |
2007-06-14 |
ネオス テクノロジーズ インコーポレイテッド |
GlycoPEGylated follicle stimulating hormone
|
WO2005070138A2
(en)
|
2004-01-08 |
2005-08-04 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
AU2005243427B2
(en)
|
2004-05-04 |
2010-07-22 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
HUE026826T2
(en)
|
2004-10-29 |
2016-07-28 |
Ratiopharm Gmbh |
Remodeling and glycopegylation of fibroblast growth factor (FGF)
|
EP1858543B1
(en)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylated granulocyte colony stimulating factor
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US20080255026A1
(en)
|
2005-05-25 |
2008-10-16 |
Glycopegylated Factor 1X |
Glycopegylated Factor Ix
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
JP2009532351A
(en)
|
2006-03-31 |
2009-09-10 |
バクスター・インターナショナル・インコーポレイテッド |
PEGylated factor VIII
|
US20080280818A1
(en)
|
2006-07-21 |
2008-11-13 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
JP2010505874A
(en)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
Purification method for polypeptide conjugates
|
PT2101821E
(en)
|
2006-12-15 |
2014-10-03 |
Baxter Int |
Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
|
ES2406267T3
(en)
|
2007-04-03 |
2013-06-06 |
Biogenerix Ag |
Treatment methods using glycopegylated G-CSF
|
MX2009013259A
(en)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Improved process for the production of nucleotide sugars.
|
PT2197919E
(en)
|
2007-08-27 |
2014-07-17 |
Ratiopharm Gmbh |
Liquid formulation of g-csf conjugate
|
JP5542064B2
(en)
|
2008-01-22 |
2014-07-09 |
アライム ファーマシューティカルズ,インコーポレーテッド |
Tissue protective peptides and peptide analogs to prevent and treat diseases and disorders associated with tissue damage
|
CN103497246B
(en)
|
2008-02-27 |
2016-08-10 |
诺沃—诺迪斯克有限公司 |
Conjugated factor viii molecules
|
EP2672259A1
(en)
|
2008-05-13 |
2013-12-11 |
Advanced Liquid Logic, Inc. |
Droplet actuator devices, systems and methods
|
CN102497884A
(en)
|
2009-07-27 |
2012-06-13 |
巴克斯特国际公司 |
Blood coagulation protein conjugates
|
US8809501B2
(en)
|
2009-07-27 |
2014-08-19 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
ES2856055T3
(en)
|
2009-07-27 |
2021-09-27 |
Baxalta GmbH |
Glycopolysialylation of proteins other than blood clotting proteins
|
ES2590679T3
(en)
|
2009-07-27 |
2016-11-23 |
Lipoxen Technologies Limited |
Glycopolyallylation of proteins other than blood coagulation proteins
|
US8642737B2
(en)
|
2010-07-26 |
2014-02-04 |
Baxter International Inc. |
Nucleophilic catalysts for oxime linkage
|
JP6138052B2
(en)
|
2010-12-22 |
2017-05-31 |
バクスアルタ ゲーエムベーハー |
Materials and methods for conjugating water soluble fatty acid derivatives to proteins
|
WO2013156488A2
(en)
|
2012-04-16 |
2013-10-24 |
Leverton Licence Holdings Limited |
Optimised subcutaneous therapeutic agents
|
US10864253B2
(en)
|
2016-04-29 |
2020-12-15 |
Araim Pharmaceuticals, Inc. |
Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
|